Genetron Health Enters into Definitive Merger Agreement for $126M Going Private Transaction
Gunderson Dettmer is acting as U.S. legal counsel to Wuxi Guolian Development (Group) Co., Ltd., a member of the buyer consortium led by the co-founder, chairman of the board of directors and chief executive officer of Genetron Holdings Limited (“Genetron Health”, NASDAQ: GTH) on the going-private transaction of Genetron Health. Genetron Health’s implied equity value in this transaction is $126 million. The going-private transaction is expected to be completed in the first quarter of 2024.
Genetron Health is a China-based leading precision oncology platform specializing in cancer molecular profiling and leverages advanced technologies in molecular biology and data science to transform cancer treatment. Its comprehensive oncology portfolio covers the entire spectrum of cancer management, from early screening, diagnosis and treatment recommendations to continuous disease monitoring and care.
The Gunderson Dettmer deal team is led by Beijing partner Richard Chang and includes Of Counsel Peter Qiu.